HemP 

&

CBD RESEARCH

By Federal Law, we cannot make any claims, express or implied, regarding the healing aspects of Cannabidiol for any symptoms whatsoever as the FDA has not approved the use of CBD for these purposes. Although the FDA has not approved, THE SCIENCE CANNOT BE DENIED!

 

We encourage you to navigate our Research page at your leisure to see first-hand the scientific studies and clinical trails conducted concerning the beneficial results and successes with CBD.

Enjoy

-Most High Healing

 

Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action

Mlost J, Bryk M, Starowicz K. Int J Mol Sci. 2020 Nov 23;21(22):8870. doi: 10.3390/ijms21228870. PMID: 33238607; PMCID: PMC7700528.

https://pubmed.ncbi.nlm.nih.gov/33238607/

Cannabidiol in Anxiety and Sleep: A Large Case Series.

Shannon S, Lewis N, Lee H, Hughes S. Perm J. 2019;23:18-041. doi: 10.7812/TPP/18-041. PMID: 30624194; PMCID: PMC6326553.

https://pubmed.ncbi.nlm.nih.gov/30624194/

Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Front Psychol. ​Masataka N. 2019 Nov 8;10:2466. doi: 10.3389/fpsyg.2019.02466. PMID: 31787910; PMCID: PMC6856203.

https://pubmed.ncbi.nlm.nih.gov/31787910/

Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry

Babson KA, Sottile J, Morabito D. Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9. PMID: 28349316.

https://pubmed.ncbi.nlm.nih.gov/28349316/

Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.  Boehnke KF, Gagnier JJ, Matallana L, Williams DA. 2021 Jan 2:S1526-5900(20)30117-6. doi: 10.1016/j.jpain.2020.12.001. Epub ahead of print. PMID: 33400996.

https://pubmed.ncbi.nlm.nih.gov/33400996/

Chronic administration of synthetic cannabidiol induces antidepressant effects involving modulation of serotonin and noradrenaline levels in the hippocampus.

Abame MA, He Y, Wu S, Xie Z, Zhang J, Gong X, Wu C, Shen J. Neurosci Lett. 2020 Dec 31:135594. doi: 10.1016/j.neulet.2020.135594. Epub ahead of print. PMID: 33388355.

https://pubmed.ncbi.nlm.nih.gov/33388355/

Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.

S G, Hb S, K L, R T, Bs R, Ps S, F S, Ab O. Mult Scler Relat Disord. 2020 Dec 30;48:102708. doi: 10.1016/j.msard.2020.102708. Epub ahead of print. PMID: 33387864.

https://pubmed.ncbi.nlm.nih.gov/33387864/

Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.

Oláh A, Markovics A, Szabó-Papp J, Szabó PT, Stott C, Zouboulis CC, Bíró T. Exp Dermatol. 2016 Sep;25(9):701-7. doi: 10.1111/exd.13042. Epub 2016 Jun 15. PMID: 27094344.

https://pubmed.ncbi.nlm.nih.gov/27094344/

A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol.

Sunda F, Arowolo A. FASEB J. 2020 Nov;34(11):14083-14092. doi: 10.1096/fj.202000975R. Epub 2020 Sep 3. PMID: 32885502.

https://pubmed.ncbi.nlm.nih.gov/32885502/

Cannabinoids in the management of frontotemporal dementia: a case series.

Gopalakrishna G, Srivathsal Y, Kaur G. Neurodegener Dis Manag. 2021 Feb;11(1):61-64. doi: 10.2217/nmt-2020-0048. Epub 2020 Nov 16. PMID: 33190583.

https://pubmed.ncbi.nlm.nih.gov/33190583/

 

Cannabidiol-from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer.

Kis B, Ifrim FC, Buda V, et al. Int J Mol Sci. 2019;20(23):5905. Published 2019 Nov 25. doi:10.3390/ijms20235905

https://pubmed.ncbi.nlm.nih.gov/31775230//

 

Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts.

Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G.  Cell Death Dis. 2020;11(8):714. Published 2020 Sep 1.  doi:10.1038/s41419-020-02892-1

https://pubmed.ncbi.nlm.nih.gov/32873774/

 

A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol

Sunda F, Arowolo A. [published online ahead of print, 2020 Sep 3]. FASEB J. 2020;10.1096/fj.202000975R. doi:10.1096/fj.202000975R

https://pubmed.ncbi.nlm.nih.gov/32884847/

 

A systematic review of the antipsychotic properties of cannabidiol in humans.

Iseger TA, Bossong MG. Schizophr Res. 2015;162(1-3):153-161. doi:10.1016/j.schres.2015.01.033

https://pubmed.ncbi.nlm.nih.gov/25801536/

 

Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts.

Kogan NM, Melamed E, Wasserman E, et al. Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. J Bone Miner Res. 2015;30(10):1905-1913. doi:10.1002/jbmr.2513

https://pubmed.ncbi.nlm.nih.gov/25801536/

 

Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms.

Calpe-López C, García-Pardo MP, Aguilar MA. Molecules. 2019;24(14):2583. Published 2019 Jul 16. doi:10.3390/molecules24142583

https://pubmed.ncbi.nlm.nih.gov/31315244/

 

Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans

Manini AF, Yiannoulos G, Bergamaschi MM, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015;9(3):204-210. doi:10.1097/ADM.0000000000000118

https://pubmed.ncbi.nlm.nih.gov/25748562/

 

Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.

Samanta D. Pediatr Neurol. 2019;96:24-29. doi:10.1016/j.pediatrneurol.2019.03.014

https://pubmed.ncbi.nlm.nih.gov/31053391/

 

Cannabidiol: an alternative therapeutic agent for oral mucositis?

Cuba LF, Salum FG, Cherubini K, Figueiredo MAZ.. J Clin Pharm Ther. 2017;42(3):245-250. doi:10.1111/jcpt.12504

https://pubmed.ncbi.nlm.nih.gov/28191662/

 

Cannabidiol for Epilepsy: New Hope on the Horizon?

Sanmartin PE, Detyniecki K.. Clin Ther. 2018;40(9):1438-1441. doi:10.1016/j.clinthera.2018.07.020

https://pubmed.ncbi.nlm.nih.gov/30150078/

 

Cannabidiol, neuroprotection and neuropsychiatric disorders. 

Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Pharmacol Res. 2016;112:119-127. doi:10.1016/j.phrs.2016.01.033

https://pubmed.ncbi.nlm.nih.gov/26845349/

 

Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. 

Poleg S, Golubchik P, Offen D, Weizman A. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:90-96. doi:10.1016/j.pnpbp.2018.08.030

https://pubmed.ncbi.nlm.nih.gov/30171992/

 

Is Cannabidiol a Promising Substance for New Drug Development? A Review of its Potential Therapeutic Applications.

Noreen N, Muhammad F, Akhtar B, Azam F, Anwar MI. Crit Rev Eukaryot Gene Expr. 2018;28(1):73-86. doi:10.1615/CritRevEukaryotGeneExpr.2018021528

https://pubmed.ncbi.nlm.nih.gov/29773016/

 

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.

White CM. J Clin Pharmacol. 2019;59(7):923-934. doi:10.1002/jcph.1387

https://pubmed.ncbi.nlm.nih.gov/30730563/

 

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.

Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Epidemiol Psychiatr Sci. 2018;27(4):327-335. doi:10.1017/S2045796018000239

https://pubmed.ncbi.nlm.nih.gov/29789034/

 

Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities. 

Upadhya D, Castro OW, Upadhya R, Shetty AK. Mol Neurobiol. 2018;55(8):6956-6964. doi:10.1007/s12035-018-0898-y

https://pubmed.ncbi.nlm.nih.gov/29372545/

 

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes. 

Chen JW, Borgelt LM, Blackmer AB. Ann Pharmacother. 2019;53(6):603-611. doi:10.1177/1060028018822124

https://pubmed.ncbi.nlm.nih.gov/30616356/

 

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. 

Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Molecules. 2019;24(8):1459. Published 2019 Apr 12. doi:10.3390/molecules24081459

https://pubmed.ncbi.nlm.nih.gov/31013866/

 

Is Cannabidiol the Answer for Disorders of Motivation?

Zlebnik NE, Cheer JF. Beyond the CB1 Receptor:. 

Annu Rev Neurosci. 2016;39:1-17. doi:10.1146/annurev-neuro-070815-014038

https://pubmed.ncbi.nlm.nih.gov/27023732/

 

Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.

Nona CN, Hendershot CS, Le Foll B. Exp Clin Psychopharmacol. 2019;27(4):359-369. doi:10.1037/pha0000272

https://pubmed.ncbi.nlm.nih.gov/31120285/

 

Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature. 

Fowler CJ. Clin Pharmacol Ther. 2015;97(6):587-596. doi:10.1002/cpt.84

https://pubmed.ncbi.nlm.nih.gov/25669486/

 

Immune Responses Regulated by Cannabidiol 

James M. Nichols and Barbara L.F. Kaplan 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173676/ 

 

 

More Coming Soon! 

Updated 01/06/2021